Influence of catechol-O-methyltransferase polymorphism on entacapone efficacy in Parkinson's disease

Trial Profile

Influence of catechol-O-methyltransferase polymorphism on entacapone efficacy in Parkinson's disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 May 2010

At a glance

  • Drugs Entacapone (Primary) ; Levodopa (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 04 May 2010 Actual patient number (60) added as reported by ClinicalTrials.gov.
    • 04 May 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 04 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top